Lakefront Biotherapeutics NV
LKFTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeLakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. At a $1.97B market cap, Lakefront Biotherapeutics NV ranks as a small-cap company within healthcare. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Market Cap
$1.97B
Beta
0.12
P/E (TTM)
3.51
P/E (Fwd)
-15.29
EPS (TTM)
$8.56
EPS (Fwd)
$-1.96
ROE
16.3%
ROA
10.7%
Cash
$2.98B
Total Debt
$6.4M
Free CF
$211.0M
52W Change
-3.6%
Annual Financials
Cash vs Debt
Lakefront Biotherapeutics NV holds $2.98B in cash against $6.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $211.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 16.3% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 10.7% further supports the picture of efficient asset utilization. Revenue has grown from $241.2M (2022) to $1.11B (2025), reflecting a 361% increase over the period.
The relatively low beta of 0.12 suggests LKFT is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Lakefront Biotherapeutics NV and its sector.